Invion Limited

A clinical-stage drug development company focused on the development of treatments for major market opportunities in inflammatory diseases including asthma, chronic bronchitis and lupus. Hear CMO Dr Mitchell Glass discuss the results of Invion's successful P2 clinical trial in smoking cessation.

Investor Presentation

Invion has three drug assets in development across four development programs. Two phase II clinical trials are currently underway with the 136 patient smoking cessation study due to report in Q3 2015. Read more in the latest corporate presentation